In Greece, the situation in the pharmaceutical sector has reached a full dead-end due to the constant decreases in the pharmaceutical budget, which are effected via segmental, horizontal and unfair collection measures and not via the necessary structural changes.
This was the unanimous conclusion of members at the extraordinary general meeting held last week by the Hellenic Association of Pharmaceutical Companies SFEE (comprising 69 drugmakers: 31 Greek and 38 multinational subsidiaries).
The nation’s drugmakers are now owed some 1.2 billion euros ($1.62 billion), it was pointed out. Moreover, the adoption of horizontal collection measures, instead of structural ones, leads the industry to a dead-end and punishes innovation and Greek patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze